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INTRODUCTION
Prostate cancer continues to be the most common cancer and
the third- leading cause of cancer-related deaths among men in
the United States. Projections for 2017 indicated 161,360 new
cases of prostate cancer, along with 26,730 deaths from the disease
(1, 2). Prostate cancer incidence is much lower in Asian countries
including Japan than that of Western countries. However, prostate
cancer incidence in Asian countries has been on a steady increase
during the past few decades (3, 4). Extraprostatic extension of
prostate cancer is defined as pT3a in the tumor, lymph node, and
metastasis staging system for prostate cancer, and it is well -
established as being associated with a poor prognosis. This feature
must be identified accurately for optimal patient management after
radical prostatectomy (5-7). The prostate is surrounded by pe-
riprostatic adipose tissue. Therefore, an admixture of tumor cells
with periprostatic adipose tissue (Figure 1) is the most common
finding of extraprostatic extension (8, 9).
Adipose tissue is composed mainly of adipocytes, although addi-
tional cell types are present, including pericytes, monocytes,
macrophages, lymphocytes, fibroblasts, vascular endothelial cells,
and pluripotent stem cells. Previously, adipose tissue was thought
to play limited physiological roles mainly as energy storage and
protection from cold temperatures. Currently, adipose tissue is rec-
ognized as an active endocrine organ, secreting growth factors,
chemokines, or pro- inflammatory molecules termed ‘adipokines’
that can regulate metabolism and the immune system. Physiologi-
cally, adipokines regulate appetite, lipid metabolism, glucose ho-
meostasis, insulin sensitivity, angiogenesis, blood pressure, and
inflammatory processes (10). Obesity is defined by increased adi-
pose mass arising from an energy imbalance. Adipocyte hypertro-
phy during obesity causes adipose dysfunction and inflammation
by increasing the secretion of pro- inflammatory adipokines from
adipocytes (11). Alterations of adipocyte biology associated with
adipocyte hypertrophy affect systemic organs. Epidemiologically,
obesity is related to the risk of many types of cancers, including
esophageal, gastric, colorectal, biliary, pancreatic breast, en-
dometrial, ovarian, and kidney cancers (12-14). In addition, obe-
sity is associated with the progression of many cancers, including
prostate, breast, endometrial, kidney, pancreatic, esophageal, and
thyroid cancers (15-19). Furthermore, direct crosstalk between
normal adipocytes and cancer cells can exist at the front of cancer
invasion to adipose tissue (20-22). Thus, growing evidence sug-
gests crucial roles for adipose tissue in the development of several
cancers.
In this article, we review the contribution of adipose tissue to
prostate cancer development, including bone metastasis.
1. OBESITY AND PROSTATE CANCER
It is estimated that overweight and obesity could account for
14% of all cancer deaths in men and 20% of all cancer deaths in
women in the United States (23). Epidemiologic studies have found
that the relationship between obesity and the incidence of prostate
cancer is unclear. On the other hand, obesity is associated with
prostate cancer mortality (12-14). In addition, obesity and hyper-
tension were each associated with an increased risk of biochemical
recurrence of prostate cancer after radical prostatectomy, inde-
pendent of age at diagnosis and tumor pathological features (24).
Interestingly, several studies suggest that obesity reduces the risk
of localized, low-grade, and nonaggressive prostate cancer, al-
though it increases the risk of advanced, high-grade, and aggres-
sive prostate cancer (25, 26). Obesity has also been associated with
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the presence of prostatic intraepithelial neoplasia in benign speci-
mens and with future prostate cancer risk after an initial benign
finding. Therefore, obesity should be taken into account in the
clinical follow-up plan after a benign biopsy (27).
A major mechanism to explain the link between obesity and
cancer includes insulin and the IGF-1 axis, sex steroids, and
adipose tissue-derived cytokines. They are linked through insulin
resistance (28). Other possible mechanisms include fatty acid-
induced inflammation, oxidative stress, endoplasmic reticulum
stress, and hypoxia.
Insulin-IGF-1 axis
Circulating insulin levels correlate positively with increasing
body mass index, and many obese persons are insulin-resistant.
The evidence is mounting that insulin resistance is a risk factor for
cancer development. It is suggested that hyperinsulinemia may
contribute to cancer development through the growth-promoting
effect of elevated insulin levels (29, 30). Obesity and prolonged
hyperinsulinemia are associated with increases in the levels of free
or bioactive IGF-1 due to reduced production of IGF-binding pro-
teins, which normally bind IGF-1 and inhibit its action. Through
the interaction with the IGF receptor, IGF activates downstream
signaling pathways that affect the growth of cancer cells by the
promotion of mitogenic pathways, induction of neovascularization,
and inhibition of apoptosis. Insulin itself has anabolic, antiapop-
totic, and mitotic effects (12, 31, 32).
Epidemiological data suggest that high levels of circulating IGF-1
are associated with an increased risk of prostate cancer develop-
ment (33). IGF-1 signaling is elevated in prostate cancer com-
pared to prostate epithelium and is associated with tumor progres-
sion (34, 35). In addition, overexpression of the IGF-1 receptor has
been shown in prostate cancer (36).
Sex hormones
Androgens have been known to play an important role in normal
prostate development and function, as well as for the growth and
progression of prostate cancer. However, it has been suggested
that there is no association between the plasma concentration of
androgens and prostate cancer risk (37). Obesity is associated
with a decrease in testosterone levels (38) and the synthesis of sex
hormone-binding globulin (SHBG), which binds to sex hormones
including testosterone and dihydrotestosterone and regulates
their effects (39). A significant association was shown between low
serum testosterone levels and tumor stage and extraprostatic
tumor spread in prostate cancer patients (40). Furthermore, the
levels of testosterone were significantly lower in patients with pros-
tate cancer than in those with benign prostatic hyperplasia (41).
These results suggest that the low testosterone levels in obese men
may be related to prostate cancer development. However, the exact
mechanisms are still unknown.
Adipose tissue-derived cytokines
Adipose tissues in obesity are infiltrated by a large number of
inflammatory cells (e.g. macrophages and leukocytes), and this
recruitment is linked to systemic inflammation and insulin resis-
tance (42, 43). The inflammation induces the generation of reactive
oxygen species that act as tumor promoters at a low concentrations
(44). Adipocytes, other stromal cells, and infiltrating inflammatory
cells in adipose tissue secrete several adipokines and other cytoki-
nes, which have been implicated to play a pivotal role in the
development of obesity -related cancer (45). Adipokines are de-
fined as hormone- like polypeptides that are actively secreted by
white adipose tissue, and they include cytokines (e.g. interleukin-6
(IL-6) and tumor necrosis factor (TNF)-α), angiogenic factors
(e.g. vascular endothelial growth factor (VEGF) and apelin), and
other factors (e.g. leptin and adiponectin) (46). Several adipokines
have been recognized to have multiple effects on prostate cancer
cells.
2. MAJOR ADIPOKINES (LEPTIN, IL-6, AND ADI-
PONECTIN) AND PROSTATE CANCER
Leptin
Leptin, a polypeptide hormone that is mainly produced by adipo-
cytes, acts as a major regulator for appetite and energy homeostasis
via its action on specific receptors expressed in the hypothala-
mus (47). The levels of leptin in plasma are correlated with the
percentage of body fat (48, 49). This observation suggests that
most obese persons are insensitive to endogenous leptin production.
Epidemiologically, the association between serum leptin levels
and prostate cancer risk is controversial. Stattin et al. reported that
Figure 1. Extraprostatic extension of prostate cancer. (a) Prostate cancer invasion into periprostatic adipose tissue. Scale = 400 μm. PC, prostate
cancer cells ; A, adipose tissue. (b) Prostate cancer cells grow in proximity to adipocytes. Scale = 100 μm. PC, prostate cancer cells ; A, adipose
tissue.
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moderately elevated plasma leptin concentrations are associated
with later development of prostate cancer (50). Another study
showed that elevated plasma leptin concentrations are associated
with an increased risk of high-volume prostate cancer (tumors
0.5 cc in volume or with histologic evidence of extraprostatic exten-
sion but without metastases) (51). On the other hand, several
studies suggest that there is no association between serum leptin
levels and prostate cancer risk (52, 53).
In human prostate tissue, leptin receptors have been detected in
normal epithelium, prostatic high-grade intraepithelial neoplasia,
and carcinoma by immunohistochemistry (50). DU145 and PC-3
human prostate cancer cells have also been found to express leptin
receptors, and leptin treatment had mitogenic and anti -apoptotic
effects on these cells with phosphatidyl - inositol 3 -kinase (PI3K)
and mitogen-activated protein kinase (MAPK) pathway activation
(54, 55). Moreover, long-term exposure to leptin enhanced prolif-
eration, invasion, and migration of prostate cancer cells with in-
creased cyclin D1 expression and decreased p21 expression, sug-
gesting the participation of leptin in cell cycle progression (56).
Single nucleotide polymorphism (SNP) in exon 4 of the leptin re-
ceptor gene was significantly associated with prostate cancer-
specific mortality (57).
IL-6
Serum IL-6 has demonstrated the strongest relationship with
obesity and insulin resistance (58). In adipose tissue, the main
sources of IL-6 are infiltrating macrophages and stromal cells.
However, adipocytes also produce IL-6 (59). Serum IL-6 levels
were significantly higher in patients with metastatic or hormone-
refractory prostate cancer than in normal controls or patients with
localized disease (60, 61), and they were associated with shorter
survival time in patients with hormone-refractory prostate cancer
(62). Exogenous IL-6 stimulated growth in hormone-sensitive
LNCaP prostate cancer cells, but not hormone- insensitive DU145
and PC-3 cells (63). In a tumor xenograft model, when LNCaP cells
continuously treated with IL-6 were inoculated into nude mice,
tumor volumes were larger than those of their controls cultured
without IL-6 treatment (64). Increased IL-6 receptor expression
was observed in human prostate cancer tissue, compared with nor-
mal prostate tissue, and high levels of IL-6 receptor expression in
prostate cancer were associated with higher rates of cell prolifera-
tion on immunohistochemistry (65). Thus, IL-6 appears to act
primarily as a paracrine growth factor for hormone-sensitive
prostate cancer. However, its main action may shift to an autocrine
mode as hormone resistance develops in prostate cancer.
Adiponectin
Adiponectin is a protein displaying structural similarities to
collagen and TNF-α, and it is mainly secreted by adipocytes (66)
and regulates glucose and lipid metabolism, vascular remodeling,
and bone homeostasis. In addition, adiponectin has defensive ef-
fects against inflammation and insulin resistance (67-70). In hu-
mans, plasma concentrations of adiponectin are significantly
lower in obesity and insulin-resistant states (71, 72). Adiponectin
can bind to three receptors, AdipoR1, AdipoR2, and T-cadherin
(73). Through the interaction with AdipoR1 and AdipoR2, adi-
ponectin shows antidiabetic effects (74).
Epidemiological studies have reported that plasma adiponectin
levels were significantly lower in patients with prostate cancer
than in benign prostatic hyperplasia (BPH) patients or healthy con-
trols (75, 76). Tan et al. examined the immunohistochemical ex-
pressions of adiponectin in BPH cases and prostate cancer cases
with low Gleason score (7) Gleason score 7 or high Gleason score
(7). The results suggested that decreased adiponectin expres-
sion was associated with prostate cancer progression. Further-
more, silencing of adiponectin induced proliferation and invasion
in 22RV1 human prostate cancer cells via the epithelial - to -mese-
nchymal transition process (77). AdipoR2 expression levels in
prostate cancer cells were positively associated with cell prolifera-
tion, with expression of fatty acid synthase, and with angiogenesis
(78). These results suggests a positive relationship between
AdipoR2 and prostate cancer development.
3. TUMOR MICROENVIRONMENT AND ADIPOSE
TISSUE
Periprostatic adipose tissue was present on 48% of all prostatic
surfaces. The distribution of adipose tissue in the anterior, poste-
rior, right, and left prostatic surfaces was 44%, 36%, 59%, and 57%,
respectively (79). When prostate cancer cells invade into pe-
riprostatic adipose tissue, adipose tissue contributes to create the
tumor microenvironment. It has been recognized that the tumor
microenvironment is crucial for tumor progression and metastasis.
In such cases, adipokines play a central role. Adipokines act in
paracrine, autocrine, and endocrine manners (80). However,
paracrine and autocrine signaling may be a key action in the tumor
microenvironment. For example, IL-6 levels in periprostatic adi-
pose tissue harvested from prostate cancer patients undergoing
radical prostatectomy were approximately 375 times higher than in
patient-matched serum. In addition, a higher Gleason score was
correlated with high IL-6 levels (81). Fain et al. reported that the
levels of VEGF and IL-6 released from visceral adipose tissue were
significantly higher than those from subcutaneous adipose tissue
(82). Thus, in cases of extraprostatic extension, prostate cancer
cells are directly exposed to huge amounts of adipokines released
from periprostatic adipose tissue. Furthermore, increased pe-
riprostatic adipose tissue due to obesity etc. may modify the tumor
microenvironment and accelerate tumor progression. Actually, in-
creasing periprostatic adipose tissue thickness, measured by
transrectal ultrasonography as the distance between the prostate
and the pubic bone, was associated with prostate cancer and high-
grade prostate cancer (83).
In the tumor microenvironment, matrix metalloproteinases
(MMPs) play an important role in cancer progression, as well as
adipokines. Periprostatic adipose tissue from prostate cancer pa-
tients released higher amounts of pro-MMP-9 than that from BPH
patients (84). Supernatants from whole periprostatic adipose tissue
showed increased activities of both MMP2 and MMP9, and they
promoted proliferation and migration of PC-3 cells, compared with
those from the stromal vascular fraction of adipose tissue (85).
These findings suggest that MMPs from periprostatic adipose
tissue modulate the tumor microenvironment and promote pros-
tate cancer cell survival and migration.
When cancer cells invade into adipose tissue, direct contact
between cancer cells and adipocytes may occur. Dirat et al. re-
ported that adipocytes adjacent to cancer cells at the invasive front
demonstrated a decrease in more differentiated adipose markers
and overexpressions of several inflammatory cytokines in breast
cancer. In addition, the levels of IL-6 in tumor surrounding adipo-
cytes were higher in cases with tumors of larger size and/or with
lymph node involvement. These adipocytes were termed “cancer-
associated adipocytes” (20). Thus the cross- interactions between
breast cancer cells and adipocytes modify each other’s characteris-
tics/phenotypes, leading cancer cells to become more aggressive.
Nieman et al. indicated another mechanism of cancer progres-
sion by direct contact between cancer cells and adipocytes. Co-
culture of adipocytes and ovarian cancer cells promoted in vitro
and in vivo tumor growth. In this culture system, the direct
transfer of lipids from adipocytes to ovarian cancer cells, lipolysis in
adipocytes, and β -oxidation in cancer cells were induced, suggest-
ing that adipocytes act as an energy source for the cancer cells.
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From the results of protein array and immunohistochemical analy-
ses in omental metastases compared to primary ovarian tumors,
FABP4 was found to play an important role in ovarian cancer me-
tastasis (86). FABP4, also known as aP2, is a member of the cyto-
plasmic fatty acid binding protein multigene family that is associ-
ated with insulin resistance, type 2 diabetes mellitus, and cardio-
vascular disease (87-89). FABP4 is released from adipocytes
and is abundantly present in human serum. Serum FABP4 levels
are linked to obesity (87). We showed the involvement of FABP4 in
human prostate cancer cell progression. In an in vitro study, FABP4
treatment promoted prostate cancer cell invasion, and the promot-
ing effects were reduced by a FABP4 inhibitor, which inhibits
FABP4 binding to fatty acids. Uptake of FABP4 into prostate cancer
cells following FABP4 treatment was observed on immunohisto-
chemistry. A FABP4 inhibitor also reduced subcutaneous growth
and lung metastasis of prostate cancer cells in vivo. These results
suggest that FABP4 may act as a carrier of an energy source for the
prostate cancer cells. In addition, FABP4 treatment activated the
phosphoinositide 3-kinase (PI3K)/Akt pathway, with or without a
FABP4 inhibitor, suggesting that FABP4 exerts its effect on pros-
tate cancer cells through several pathways (90). Thus, FABP4
might be a key molecule to understand the mechanisms underly-
ing the adipose tissue-prostate cancer progression link. Possible
mechanisms involving FABP4 in prostate cancer progression are
shown in Figure 2.
4. BONE MARROW ADIPOCYTES AND CANCER
METASTASIS
Bone is the common metastatic site of prostate cancer, and bone
metastasis is seen in 90% of patients with metastatic prostate
cancer. In fact, 86% of these patients had only bone metastases (91).
Bone metastasis of prostate cancer is a multistep process including
detachment of cancer cells from the primary tumor, travel of the
cells through the blood vessels or lymphatics, attachment to bone
tissue, and development of metastatic tumor in the bone. Figure 3
shows the histology of prostate cancer bone metastases. Prostate
cancer metastases cause an osteoblastic, osteolytic, or mixed bone
response (92-94). In osteolytic metastases, cancer cells produce
osteoclastic factors such as parathyroid hormone-related protein
(PTHrP) and transforming growth factor β (TGFβ), which stimu-
late osteoblasts and stromal cells to express receptor activator of
NF kappa B (54) ligand (RANKL). The binding of RANKL to its
receptor, RANK, on osteoclasts drives bone resorption and release
of growth factors from the matrix, which supports cancer cell
growth (95, 96). On the other hand, osteoblastic metastases are
formed by cancer cell growth with new bone formation. Some
tumor-associated factors, including endothelin-1 and Wnts, have
been proposed to stimulate osteoblast activity directly, and other
factors including urokinase-type plasminogen activator activate
proteases such as PSA, which enhance the osteosclerotic process
either via activation of the quiescent forms of TGFβ or via degrada-
tion of PTHrP (95, 97, 98).
Although bone contains few adipocytes at birth, aging causes an
increase in the number of marrow adipocytes (99). In addition,
obesity is associated with an increase of bone marrow adipose
tissue (100). Therefore, it is possible that marrow adipose tissue
may affect the growth and survival of metastatic cancer cells.
Actually, when breast cancer cells were co-cultured with cancel-
lous human bone tissue fragments, cancer cell migration toward
tissue-conditioned medium was enhanced in association with in-
creasing levels of leptin and IL-1β. Immunohistochemistry of frag-
ments showed breast cancer cell colonization within the marrow
adipose tissue compartment (101).
IGF-1 is the most abundant growth factor that is deposited in the
bone matrix (102). Although IGF-1 is a key factor in the endocrine
regulation of body composition, IGF-1 also plays an important
role in the maintenance of bone mineral density. IGF-1 is released
from the bone matrix in response to bone resorption. IGF-1 in-
duces the differentiation of osteoblasts and stimulates expression
and secretion of RANKL in osteoblasts. RANKL promotes osteo-
clastogenesis. As a result, new bone is formed at bone resorption
sites (103-105). Furthermore, IGF-1 stimulates LNCaP cell growth
(106). C4-2 human prostate cancer cells, a subline of LNCaP hav-
ing a proclivity to form osteoblastic bone metastases, produced
higher amounts of IGF-1 than LNCaP. IGF-I mRNA expression
in C4-2 cells was substantially increased in the presence of exoge-
nous IGF-I. These results suggest the contribution of the IGF-I
axis to the osteoblastic metastases of prostate cancer (107).
Whereas IL-6 is one of the major adipokines, it also plays a
profound role in bone metabolism. Acting via stromal/osteoblastic
cells, IL-6 stimulates osteoclastogenesis. Moreover, IL-6 can pro-
mote differentiation of osteoblasts toward a more mature pheno-
type (108). Therefore, in the bone microenvironment, metastatic
cancer cells may be exposed to large amounts of IL-6 from both
stromal/osteoblastic cells and adipocytes. Actually, it has been
suggested that IL-6 is involved with the mechanisms of bone me-
tastasis. In a mouse model of bone metastasis, administration of a
high-fat diet increased melanoma cell growth in the bone marrow
with induction of osteopontin and IL-6. Immunofluorescence stain-
ing of IL-6 showed that higher numbers of bone marrow adipo-
cytes expressing IL-6 were observed in the vicinity of tumor cells
(109). Culture medium from PC-3 human prostate cancer cells in-
duced IL-6 gene expression in osteoblast - like MC3T3-E1 cells
and promoted osteoclastogenesis in vitro. IL-6 was highly ex-
pressed in PC-3 cells growing in the bones of SCID mice and
human bone metastases (110). On the other hand, culture medium
from human osteoblast - like HOBIT cells induced proliferation and
PSA expression in human prostate cancer cells, LNCaP, C4-2B,
and VCaP. These effects were inhibited by treatment with anti - IL-6
antibody, suggesting that IL-6 secreted from osteoblasts promotes
prostate cancer growth (111).
Figure 2. Possible mechanisms involving fatty acid -binding protein 4
(FABP4) in prostate cancer progression. FABP4 binding to free fatty
acids (FFAs) is taken up into prostate cancer cells, and FFAs may be
used as an energy source for prostate cancer development. In addition,
FABP4 can activate the phosphatidyl - inositol 3 -kinase (PI3K)/Akt path-
way without being taken up into prostate cancer cells. Obesity increases
the serum levels of FABP4.
12 H. Uehara, et al. Adipose tissue and prostate cancer
As thus far described, in the microenvironment of bone metasta-
ses, tumor cells, osteoblasts, osteoclasts, adipocytes, and other
stromal cells interacting with each other and organize a complex
system (Figure 4). Because aging is associated with both cancer
risk and amount of bone marrow adipose tissue, bone marrow
adipose tissue may be one of the key factors in bone metastasis.
However, its roles are poorly understood.
5. CONCLUSIONS
The data presented in this review suggest that adipose tissue
plays an important role in the development of prostate cancer,
including tumor growth, invasion, and metastasis. Prostate cancer
cells with extracapsular invasion form a new microenvironment in
periprostatic adipose tissue. In the process, cancer cells are
thought to have direct or indirect interactions with adipocytes.
Moreover, obesity may modify these interactions and promote
tumor progression. Bone is a favorite metastatic site of prostate
cancer and contains increasing adipose tissue with age. Bone
marrow adipose tissue interacts with tumor cells, osteoblasts, and
other stromal cells, and it participates in the organization of the
tumor microenvironment. Whereas adipokines seem to be key
molecules in the relationship between cancer cells and adipose
tissue, several other mechanisms are suggested. A deeper under-
standing of the roles of adipose tissue in prostate cancer progres-
sion will lead to more effective therapeutic strategies for prostate
cancer.
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